Endogenous plant expression enhancer

Patent metadata

Field	Value
Publication number	US-12146145-B2
Application number	US-201917439155-A
Country	US
Kind code	B2
Filing date	Mar 14, 2019
Priority date	Mar 14, 2019
Publication date	Nov 19, 2024
Grant date	Nov 19, 2024

Abstract

An isolated expression enhancer active in a plant, portion of a plant or plant cell, the expression enhancer is provided. The isolated expression enhancer may be selected from the group consisting of nbEPI42 (SEQ ID NO:1); nbSNS46 (SEQ ID NO:2); nbCSY65 (SEQ ID NO:3); nbHEL40 (SEQ ID NO:4); and nbSEP44 (SEQ ID NO:5). Methods for using the isolated expression enhancer are also provided.

First claim

What is claimed is:

1. A nucleic acid comprising an expression enhancer operatively linked with a heterologous nucleotide sequence encoding a protein of interest, the expression enhancer consisting of:
nbCSY65 (SEQ ID NO:3).

2. The nucleic acid of claim 1 , where the heterologous nucleotide sequence encodes a viral protein or an antibody.

3. The nucleic acid of claim 2 , wherein the viral protein is an influenza protein or a norovirus protein.

4. The nucleic acid of claim 3 , wherein the influenza protein is a hemagglutinin protein selected from the group of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and an influenza type B hemagglutinin.

5. The nucleic acid of claim 3 , wherein the norovirus protein is a VP1, a VP2, or a combination thereof selected from the group of GI.1, GI.2, GI.3, GI.5, GI.7, GII. 1, GII.2, GII.3, GII.4, GII.5, GII.6, GII. 7, GII. 12, GII. 13, GII. 14, GII. 17 and GII.21.

6. A plant expression system comprising one or more than one of the nucleic acid of claim 1 .

7. A plant expression system comprising one or more than one of nucleic acid of claim 2 .

8. A plant expression system comprising one or more than one of the nucleic acid of claim 3 .

9. A plant expression system comprising one or more than one of the nucleic acid of claim 4 .

10. A plant expression system comprising one or more than one of the nucleic acid of claim 5 .

11. The plant expression system of claim 6 further comprising a comovirus 3′ UTR.

12. A method of producing a protein of interest in a plant, a portion of a plant, or a plant cell, comprising,
introducing into the plant, the portion of a plant, or the plant cell, in a stable or transient manner, the plant expression system of claim 6 comprising the one or more than one nucleic acid, and
incubating the plant or the portion of a plant under conditions that permit expression of each of the heterologous nucleotide sequence encoding the protein of interest.

13. The method of claim 12 , wherein the protein of interest is a viral protein.

14. The method of claim 13 , wherein the viral protein is an influenza protein or a norovirus protein.

15. The method of claim 14 , wherein the influenza protein is a hemagglutinin protein selected from the group of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and an influenza type B hemagglutinin.

16. The method of claim 14 , wherein the norovirus protein is a VP1, a VP2, or a combination thereof selected from the group of GI.1, GI.2, GI,3, GI.5, GI.7, GII. 1, GII.2, GII.3, GII.4, GII.5, GII.6, GII. 7, GII. 12, GII. 13, GII. 14, GII. 17 and GII.21.

17. The method of claim 12 , wherein the protein of interest is a multimeric protein, and the step of introducing involves co-expressing two or more than two of the heterologous nucleotide sequence, each of the two or more than two of the heterologous nucleotide sequence encoding a component of the multimeric protein.

18. A plant, portion of a plant, or a plant cell, transiently transformed or stably transformed with the plant expression system of claim 6 .

19. The nucleic acid of claim 1 , wherein the expression enhancer increases expression of the heterologous nucleotide sequence encoding the protein of interest in a Nicotiana benthamiana plant when compared to the level of expression of the same heterologous nucleotide sequence that is not operatively linked to the expression enhancer.

Assignees

• Mitsubishi Tanabe Pharma Corp
• Medicago Inc
• National Univ Corporation Nara Institute Of Science And Technology
• Aramis Biotechnologies Inc

Inventors

• Lavoie Pierre-Olivier
• D'Aoust Marc-Andre
• Kato Ko
• Yamasaki Shotaro

Classifications

• C12N15/8258 Primary

  for the production of oral vaccines (antigens) or immunoglobulins · CPC title

• C12N2770/18022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2770/16023

  Virus like particles [VLP] · CPC title

• C12N2770/16022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2760/16223

  Virus like particles [VLP] · CPC title